XML 31 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Mar. 31, 2013
Revenues:        
License and milestone fees $ 305 $ 22,010 $ 39,150 $ 23,372
Royalty revenue 2,558   6,946  
Research and development support 1,948 2,257 5,860 5,670
Clinical materials revenue 2,064 734 2,197 2,662
Total revenues 6,875 25,001 54,153 31,704
Operating Expenses:        
Research and development 38,280 21,318 81,171 66,674
General and administrative 6,040 4,995 18,013 16,098
Total operating expenses 44,320 26,313 99,184 82,772
Loss from operations (37,445) (1,312) (45,031) (51,068)
Other (expense) income, net (7) (39) 166 132
Net loss (37,452) (1,351) (44,865) (50,936)
Basic and diluted net loss per common share (in dollars per share) $ (0.44) $ (0.02) $ (0.53) $ (0.61)
Basic and diluted weighted average common shares outstanding (in shares) 85,684 84,279 85,375 83,923
Total comprehensive loss $ (37,452) $ (1,351) $ (44,865) $ (50,936)